ArticleDiabetes, metabolic syndrome and obesity : targets and therapy2025
Role of Myeloid-Derived Suppressor Cells (MDSCs), Specifically Monocyte-Derived MDSCs, in Type 2 Diabetes-Related Diabetic Retinopathy.
Article in Diabetes, metabolic syndrome and obesity : targets and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Myeloid-Derived Suppressor Cells (MDSCs) in Cardiovascular Risk of Obesity-Associated Diabetes.International journal of molecular sciences · 2026Review
- The Role of ULK3 in Cancer Progression: A Pan-Cancer Bioinformatics Analysis Integrated with Experimental Validation in Prostate Cancer.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The role of myeloid-derived suppressor cells (MDSCs) in the pathogenesis of diabetic retinopathy (DR) in patients with type 2 diabetes remains unclear. Thus, we aimed to determine whether these cells are involved in the pathogenesis of DR. Patients and Methods: Blood samples were collected from 42 patients with type 2 diabetes and DR and 20 age- and sex-matched healthy volunteers. MDSCs, including monocyte-derived (M-MDSCs) and granulocyte-derived (G-MDSCs) subpopulations, were detected via flow cytometry. Results: The difference in the percentage of peripheral blood M-MDSCs among the three groups was statistically significant. Significant differences were observed between proliferative DR (PDR), nonproliferative DR (NPDR), and healthy controls in terms of M-MDSC percentage. No significant differences were observed between the NPDR and healthy control groups. The percentage of peripheral blood G-MDSCs did not significantly differ among the three groups. Moreover, the proportion of M-MDSCs in the peripheral blood of patients positively correlated with fasting blood glucose and glycosylated hemoglobin levels. Conclusion: The percentage of M-MDSCs in peripheral blood was significantly higher in the PDR group and positively correlated with fasting blood glucose and glycosylated hemoglobin levels. Our findings suggest that M-MDSCs, particularly in the proliferative stage of DR, may serve as potential biomarkers for disease progression and offer insights into future clinical or therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.